A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study evaluating the efficacy and safety of CNTO 148 [golimumab] administered subcutaneously in symptomatic subjects with severe persistent asthma

Trial Profile

A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study evaluating the efficacy and safety of CNTO 148 [golimumab] administered subcutaneously in symptomatic subjects with severe persistent asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Golimumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jul 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Results reported as published in the American Journal of Respiratory and Critical Care Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top